Curis Inc. (CRIS), a biotechnology company developing novel therapies for slowing or preventing the progression of cancer and prolonging life, has several important clinical trial milestones lined up for the end of this year.
The company's lead drug candidate is Emavusertib, a first-in class IRAK4 inhibitor in phase I/II clinical studies in leukemia and lymphoma, dubbed TakeAim Leukemia and TakeAim Lymphoma.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com